In Brief: NAD trims BPI claims, formula price-fixing in China, FDA warns Formulife and identifies spiked supplements, NBTY’s consumer redress
This article was originally published in The Tan Sheet
Executive Summary
BPI discontinues claims at NAD’s behest; China levies fines for infant formula price-fixing; Public Citizen pans OTC Oxytrol; FDA advises ProNatural supplements cannot be topical; FDA warns Formulife on DMAA; FDA uncovers more spiked supplements; NBTY pays back consumers over omega-3 claims; Algean reminded about re-inspection fee.
You may also be interested in...
NDAC Puts Hitch In Oxytrol Switch With Negative Self-Selection Vote
In a 6-5 vote, FDA’s Nonprescription Drugs Advisory Committee said Merck did not show that consumers can appropriately self-select to use Oxytrol for Women in an OTC setting. The company expects to hear from FDA on its Rx-to-OTC switch application by the end of January.
In Brief
FDA softens disclaimer for green tea QHC; Formulife/Purus covers spectrum of violations; NAD refers Schick case to FTC; Genomma drops Prestige Brands board bid.
NBTY Agrees To $2.1M Settlement With FTC For False DHA Claims
The Federal Trade Commission's ongoing crackdown on "bogus" health claims leads to a $2.1 million settlement with NBTY and two subsidiaries to resolve charges they overstated the amount and benefit of DHA in children's multivitamins.